These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 28470713)

  • 21. Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim.
    Posch M; Maurer W; Bretz F
    Pharm Stat; 2011; 10(2):96-104. PubMed ID: 22328314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controlling the family-wise error rate in multi-arm, multi-stage trials.
    Crouch LA; Dodd LE; Proschan MA
    Clin Trials; 2017 Jun; 14(3):237-245. PubMed ID: 28545335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adaptive graph-based multiple testing procedures.
    Klinglmueller F; Posch M; Koenig F
    Pharm Stat; 2014; 13(6):345-56. PubMed ID: 25319733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sample size of thorough QTc clinical trial adjusted for multiple comparisons.
    Tsong Y; Sun A; Kang SH
    J Biopharm Stat; 2013; 23(1):57-72. PubMed ID: 23331221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Properties of multiple intersection-union tests for multiple endpoints in combination therapy trials.
    Westfall PH; Ho SY; Prillaman BA
    J Biopharm Stat; 2001; 11(3):125-38. PubMed ID: 11725927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Group sequential designs with prospectively planned rules for subpopulation enrichment.
    Rosenblum M; Luber B; Thompson RE; Hanley D
    Stat Med; 2016 Sep; 35(21):3776-91. PubMed ID: 27076411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adding new experimental arms to randomised clinical trials: Impact on error rates.
    Choodari-Oskooei B; Bratton DJ; Gannon MR; Meade AM; Sydes MR; Parmar MK
    Clin Trials; 2020 Jun; 17(3):273-284. PubMed ID: 32063029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficient group sequential designs when there are several effect sizes under consideration.
    Jennison C; Turnbull BW
    Stat Med; 2006 Mar; 25(6):917-32. PubMed ID: 16220524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Data-driven analysis strategies for proportion studies in adaptive group sequential test designs.
    Wassmer G
    J Biopharm Stat; 2003 Nov; 13(4):585-603. PubMed ID: 14584710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A parametric multiple test procedure to adaptive group-sequential trials allowing for mid-term modifications.
    Jin M
    Contemp Clin Trials; 2020 Mar; 90():105955. PubMed ID: 32028024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A group sequential, response-adaptive design for randomized clinical trials.
    Karrison TG; Huo D; Chappell R
    Control Clin Trials; 2003 Oct; 24(5):506-22. PubMed ID: 14500050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A modified varying-stage adaptive phase II/III clinical trial design.
    Dong G; Vandemeulebroecke M
    Pharm Stat; 2016 Jul; 15(4):368-78. PubMed ID: 27264007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of adaptive allocation rules for group-sequential binary response clinical trials.
    Morgan CC; Stephen Coad D
    Stat Med; 2007 Apr; 26(9):1937-54. PubMed ID: 16981177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methods for flexible sample-size design in clinical trials: Likelihood, weighted, dual test, and promising zone approaches.
    Shih WJ; Li G; Wang Y
    Contemp Clin Trials; 2016 Mar; 47():40-8. PubMed ID: 26674739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bayesian basket trial design with false-discovery rate control.
    Zabor EC; Kane MJ; Roychoudhury S; Nie L; Hobbs BP
    Clin Trials; 2022 Jun; 19(3):297-306. PubMed ID: 35128970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Designing Issues in Confirmatory Adaptive Population Enrichment Trials.
    Wassmer G; Dragalin V
    J Biopharm Stat; 2015; 25(4):651-69. PubMed ID: 24905739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Group sequential t-test for clinical trials with small sample sizes across stages.
    Shao J; Feng H
    Contemp Clin Trials; 2007 Sep; 28(5):563-71. PubMed ID: 17434814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interval and point estimation in adaptive Phase II trials with binary endpoint.
    Nhacolo A; Brannath W
    Stat Methods Med Res; 2019 Sep; 28(9):2635-2648. PubMed ID: 29921157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A variational approach to optimal two-stage designs.
    Pilz M; Kunzmann K; Herrmann C; Rauch G; Kieser M
    Stat Med; 2019 Sep; 38(21):4159-4171. PubMed ID: 31264243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Designs for adding a treatment arm to an ongoing clinical trial.
    Bennett M; Mander AP
    Trials; 2020 Mar; 21(1):251. PubMed ID: 32143729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.